Background: The initiation of oral anticoagulation therapy after valve replacement surgery requir... more Background: The initiation of oral anticoagulation therapy after valve replacement surgery requires strict monitoring because these patients are at high risk for the development of thrombotic complications and present an increased risk of bleeding. Objectives: The aim of this study was to examine the total healthcare costs of oral anticoagulant treatment with vitamin K antagonists in patients with metallic prosthetic valves in the mitral position. Methods: Data from clinical records were used in the study including international normalized ratio results, number of medical visits, type of anticoagulant, use of rescue medication and hospital admissions from related complications. The drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included in the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the diagnosis-related group price for each case. Results: We collected data from 1...
Venous thromboembolic disease and cancer: a common association INTRODUCCIÓN La asociación entre e... more Venous thromboembolic disease and cancer: a common association INTRODUCCIÓN La asociación entre enfermedad tromboembólica venosa (ETEV) y cáncer fue descrita por vez primera por Jean-Baptiste Bouillaud en el año 1823 (1); más tarde, en el año 1865 Armand Trousseau describía esta asociación de una manera más detallada (2), dando nombre al síndrome de Trousseau como una entidad de carácter paraneoplásico consistente en la activación sistémica de la coagulación (3-4).
OBJECTIVES: Overall expenditure for the treatment of ACS imposes a heavy burden on global health ... more OBJECTIVES: Overall expenditure for the treatment of ACS imposes a heavy burden on global health care systems. As new treatments and procedures have become available in the past decade, the cost to healthcare systems has increased, yet mortality rates have remained relatively high. A recent research effort was undertaken to benchmark expenditures and outcomes in patients with ACS. The aim of this study was to understand the efficiency of resource use, in relation to mortality for patients with ACS in the UK. METHODS: A systematic literature search of 11 databases and secondary desk research were performed to identify ACS related expenditure and outcomes. Data were retrieved for UK patients with MI (STEMI, NSTEMI) and unstable angina. The reported cost data were extracted for hospitalizations, procedures, pharmaceutical treatment, and monitoring; mean annual expenditure per patient was estimated based on of these cost components. Outcomes focused on ACS mortality rate over the entire UK population. RESULTS: In the UK, the overall annual mortality rate for ACS was found to be 0.0473%. Total annual expenditure for all patients with ACS was £392,245,277 (£3,733 per patient). Results showed hospitalizations to be the main cost driver, accounting for 65.7% of the total annual cost. Procedure costs represented 24.5% of the total cost, whereas pharmaceutical treatment and monitoring costs accounted for 5.3% and 4.5%, respectively. CONCLUSIONS: The findings of this systematic review demonstrate that hospitalization cost accounts for almost two thirds of the total direct cost associated with ACS in the UK. More research and crosscountry comparison are needed to determine treatment strategies which provide greater efficiency in resource use for the management of ACS.
Background There is evidence suggesting that most thromboembolic complications could be prevented... more Background There is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation. Methods This observational study examined the clinical records of patients diagnosed with non-valvular atrial fibrillation who received anticoagulant treatment with oral vitamin K antagonists. Data from clinical records were used in the study: international normalized ratio, number of monitoring visits, type of anticoagulant, hospital admissions from complications, and concomitant medication. Drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the Diagnosis Related Group price for each case. Hospital visits costs we...
Tabla 43: Coste de las visitas según modelo y rango terapéutico (en euros). Rango terapéutico (n ... more Tabla 43: Coste de las visitas según modelo y rango terapéutico (en euros). Rango terapéutico (n o pacientes) Coste visita según modelo 1 Coste visita según modelo 2 Coste visita según modelo 3 Coste medio por paciente ± DE (p=0,092) Coste total Coste medio por paciente ± DE (p=0,05) Coste total Coste medio por paciente ± DE (p=0,092) Coste total rango 2,5-3,5 (n=102)
Background: The initiation of oral anticoagulation therapy after valve replacement surgery requir... more Background: The initiation of oral anticoagulation therapy after valve replacement surgery requires strict monitoring because these patients are at high risk for the development of thrombotic complications and present an increased risk of bleeding. Objectives: The aim of this study was to examine the total healthcare costs of oral anticoagulant treatment with vitamin K antagonists in patients with metallic prosthetic valves in the mitral position. Methods: Data from clinical records were used in the study including international normalized ratio results, number of medical visits, type of anticoagulant, use of rescue medication and hospital admissions from related complications. The drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included in the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the diagnosis-related group price for each case. Results: We collected data from 1...
Venous thromboembolic disease and cancer: a common association INTRODUCCIÓN La asociación entre e... more Venous thromboembolic disease and cancer: a common association INTRODUCCIÓN La asociación entre enfermedad tromboembólica venosa (ETEV) y cáncer fue descrita por vez primera por Jean-Baptiste Bouillaud en el año 1823 (1); más tarde, en el año 1865 Armand Trousseau describía esta asociación de una manera más detallada (2), dando nombre al síndrome de Trousseau como una entidad de carácter paraneoplásico consistente en la activación sistémica de la coagulación (3-4).
OBJECTIVES: Overall expenditure for the treatment of ACS imposes a heavy burden on global health ... more OBJECTIVES: Overall expenditure for the treatment of ACS imposes a heavy burden on global health care systems. As new treatments and procedures have become available in the past decade, the cost to healthcare systems has increased, yet mortality rates have remained relatively high. A recent research effort was undertaken to benchmark expenditures and outcomes in patients with ACS. The aim of this study was to understand the efficiency of resource use, in relation to mortality for patients with ACS in the UK. METHODS: A systematic literature search of 11 databases and secondary desk research were performed to identify ACS related expenditure and outcomes. Data were retrieved for UK patients with MI (STEMI, NSTEMI) and unstable angina. The reported cost data were extracted for hospitalizations, procedures, pharmaceutical treatment, and monitoring; mean annual expenditure per patient was estimated based on of these cost components. Outcomes focused on ACS mortality rate over the entire UK population. RESULTS: In the UK, the overall annual mortality rate for ACS was found to be 0.0473%. Total annual expenditure for all patients with ACS was £392,245,277 (£3,733 per patient). Results showed hospitalizations to be the main cost driver, accounting for 65.7% of the total annual cost. Procedure costs represented 24.5% of the total cost, whereas pharmaceutical treatment and monitoring costs accounted for 5.3% and 4.5%, respectively. CONCLUSIONS: The findings of this systematic review demonstrate that hospitalization cost accounts for almost two thirds of the total direct cost associated with ACS in the UK. More research and crosscountry comparison are needed to determine treatment strategies which provide greater efficiency in resource use for the management of ACS.
Background There is evidence suggesting that most thromboembolic complications could be prevented... more Background There is evidence suggesting that most thromboembolic complications could be prevented with adequate pharmacological anticoagulation. We estimated the direct health care costs of anticoagulant treatment with oral vitamin K antagonists in patients diagnosed with non-valvular atrial fibrillation. Methods This observational study examined the clinical records of patients diagnosed with non-valvular atrial fibrillation who received anticoagulant treatment with oral vitamin K antagonists. Data from clinical records were used in the study: international normalized ratio, number of monitoring visits, type of anticoagulant, hospital admissions from complications, and concomitant medication. Drug cost was calculated based on the official Spanish Ministry of Health price list. Monitoring expenses were included the cost of the medical supplies used in the procedures. Hospitalization costs were calculated using the Diagnosis Related Group price for each case. Hospital visits costs we...
Tabla 43: Coste de las visitas según modelo y rango terapéutico (en euros). Rango terapéutico (n ... more Tabla 43: Coste de las visitas según modelo y rango terapéutico (en euros). Rango terapéutico (n o pacientes) Coste visita según modelo 1 Coste visita según modelo 2 Coste visita según modelo 3 Coste medio por paciente ± DE (p=0,092) Coste total Coste medio por paciente ± DE (p=0,05) Coste total Coste medio por paciente ± DE (p=0,092) Coste total rango 2,5-3,5 (n=102)
Uploads
Papers by Gabriela Ene